

ASX RELEASE

12 June 2019

Capital Raising for Clinical-Enabling Studies

The Board of Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) has resolved to proceed with a capital raising to raise gross proceeds of up to A\$2.7 million.

The proceeds will be used to complete the remaining studies that are required before commencement of the Phase I healthy volunteer trial of drug candidate AMP945, as well as providing the Company with additional working capital.

The capital raising will be made up of three components:

- i. An Initial Placement of 3,600,000 ordinary shares @ \$0.10 per share to raise \$360,000;
- ii. A Directors and Management Placement of 1,700,000 ordinary shares @ \$0.10 per share to raise \$170,000; and
- iii. A 1 for 2 non-renounceable Rights Issue of shares @ \$0.10 per share to raise up to \$2.2 million.

Each subscriber under the placements and the rights issue will receive free attaching options on a 1 for 2 basis. The options will have an exercise price of \$0.15 and an expiry date of 30 June 2022.

The Directors and Management Placement is subject to shareholder approval at the Company’s Annual General Meeting which is to be held on Friday 30 August 2019.

The Initial Placement has been completed and was arranged by Taylor Collison Limited as Lead Manager.

Full details of the Rights Issue will be confirmed at the earliest opportunity.

- End -

For Further Information

Andrew J. Cooke
Director and Company Secretary
andrew@ampliatx.com
www.ampliatx.com